BEAD20260179 - ACQUISITION OF TYROSINE KINASE INHIBITORS - REGOAFENIB

This tender, identified by reference BEAD20260179, concerns the acquisition of specific pharmaceutical products: Tyrosine Kinase Inhibitors, with a particular focus on Regorafenib. Tyrosine Kinase Inhibitors (TKIs) are a class of targeted therapy drugs used primarily in cancer treatment. Regorafenib is a specific TKI used to treat certain types of cancer, such as metastatic colorectal cancer and gastrointestinal stromal tumors. This procurement is likely for a healthcare institution, hospital pharmacy, or a public health program requiring a supply of this specialized medication. The tender will specify the required dosage forms (e.g., tablets), strengths, quantities, and packaging. Adherence to strict quality control standards, regulatory approvals (e.g., from EMA or FDA), and specific storage and handling requirements are crucial for such medications. Bidders are expected to be licensed pharmaceutical distributors or manufacturers with the capability to supply Regorafenib and potentially other TKIs, ensuring authenticity, quality, and timely delivery. The evaluation criteria will heavily weigh the reliability of supply, product quality, compliance with pharmaceutical regulations, and competitive pricing for this critical oncology drug.

This is a supplies contract in the health and medical services, Monitoring Evaluation and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 7,973.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.